Switch theme
Sign up to access all valuation multiples
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
2007
808
LTM Revenue $1.6B
LTM EBITDA $696M
$6.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lantheus Holdings has a last 12-month revenue of $1.6B and a last 12-month EBITDA of $696M.
In the most recent fiscal year, Lantheus Holdings achieved revenue of $1.5B and an EBITDA of $515M.
Lantheus Holdings expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lantheus Holdings valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.3B | $1.5B | XXX | XXX | XXX |
| Gross Profit | $582M | $710M | XXX | XXX | XXX |
| Gross Margin | 45% | 46% | XXX | XXX | XXX |
| EBITDA | $491M | $515M | XXX | XXX | XXX |
| EBITDA Margin | 38% | 34% | XXX | XXX | XXX |
| Net Profit | $28.1M | $327M | XXX | XXX | XXX |
| Net Margin | 2% | 21% | XXX | XXX | XXX |
| Net Debt | $142M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Lantheus Holdings's stock price is $102.
Lantheus Holdings has current market cap of $7.0B, and EV of $6.7B.
See Lantheus Holdings trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.7B | $7.0B | XXX | XXX | XXX | XXX | $6.84 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Lantheus Holdings has market cap of $7.0B and EV of $6.7B.
Lantheus Holdings's trades at 4.3x LTM EV/Revenue multiple, and 9.6x LTM EBITDA.
Analysts estimate Lantheus Holdings's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Lantheus Holdings and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $6.7B | XXX | XXX | XXX |
| EV/Revenue | 4.4x | XXX | XXX | XXX |
| EV/EBITDA | 13.0x | XXX | XXX | XXX |
| P/E | 22.4x | XXX | XXX | XXX |
| P/E/Growth | 0.6x | XXX | XXX | XXX |
| EV/FCF | 14.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLantheus Holdings's NTM/LTM revenue growth is 6%
Lantheus Holdings's revenue per employee for the last fiscal year averaged $1.9M, while opex per employee averaged $0.7M for the same period.
Over next 12 months, Lantheus Holdings's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Lantheus Holdings's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Lantheus Holdings and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 40% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.9M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 13% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 11% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 35% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lantheus Holdings acquired XXX companies to date.
Last acquisition by Lantheus Holdings was XXXXXXXX, XXXXX XXXXX XXXXXX . Lantheus Holdings acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Lantheus Holdings founded? | Lantheus Holdings was founded in 2007. |
| Where is Lantheus Holdings headquartered? | Lantheus Holdings is headquartered in United States of America. |
| How many employees does Lantheus Holdings have? | As of today, Lantheus Holdings has 808 employees. |
| Who is the CEO of Lantheus Holdings? | Lantheus Holdings's CEO is Mr. Brian A. Markison. |
| Is Lantheus Holdings publicy listed? | Yes, Lantheus Holdings is a public company listed on NAS. |
| What is the stock symbol of Lantheus Holdings? | Lantheus Holdings trades under LNTH ticker. |
| When did Lantheus Holdings go public? | Lantheus Holdings went public in 2015. |
| Who are competitors of Lantheus Holdings? | Similar companies to Lantheus Holdings include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Lantheus Holdings? | Lantheus Holdings's current market cap is $7.0B |
| What is the current revenue of Lantheus Holdings? | Lantheus Holdings's last 12-month revenue is $1.6B. |
| What is the current EBITDA of Lantheus Holdings? | Lantheus Holdings's last 12-month EBITDA is $696M. |
| What is the current EV/Revenue multiple of Lantheus Holdings? | Current revenue multiple of Lantheus Holdings is 4.3x. |
| What is the current EV/EBITDA multiple of Lantheus Holdings? | Current EBITDA multiple of Lantheus Holdings is 9.6x. |
| What is the current revenue growth of Lantheus Holdings? | Lantheus Holdings revenue growth between 2023 and 2024 was 18%. |
| Is Lantheus Holdings profitable? | Yes, Lantheus Holdings is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
